Dr. David Paul Horowitz, MD

Dr. Horowitz practices at Columbia University Irving Medical Center in New York, New York.

Dr. Horowitz's NPI, 1841425717, was assigned on May 21, 2009. Dr. Horowitz graduated from The Johns Hopkins University School of Medicine in 2009. Dr. Horowitz holds New York license 276436.

Dr. Horowitz's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Horowitz's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Horowitz is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Horowitz to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Horowitz practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Horowitz's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Horowitz is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Horowitz's licenses on file in 6 states: New York, Florida, Virginia, Connecticut, New Jersey and District of Columbia.

Dmand AI lists bone cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lymphoma radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Horowitz treats.

CMS data shows 1,406 Medicare services from Dr. Horowitz across 15 procedure codes in 2024, for 118 Medicare patients. Medicare paid $131,326 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 118 Medicare patients who saw Dr. Horowitz in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Horowitz's median patient age at 74, with 46% women.

In 2024, Dr. Horowitz wrote 28 Medicare Part D claims for 16 patients. 100% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $137 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Horowitz for performance year 2024, reported through an alternative payment model (APM). Dr. Horowitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Horowitz as offering telehealth.

Dmand AI links 58 papers to Dr. Horowitz, published from 2010 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Pancreatic Neoplasms and Carcinoma, Squamous Cell. Dr. Horowitz has published most often in Adv Radiat Oncol. Dr. Horowitz's most frequent co-authors are Lisa Ann Kachnic, MD, Simon K. Cheng, MD, PhD and Alfred I. Neugut, MD, PhD.

Dmand AI links Dr. Horowitz to 1 clinical trial. Conditions studied include Pelvic Neoplasms.

CMS Open Payments shows 6 general payments to Dr. Horowitz from 3 drug and device companies from 2016 to 2018. Education speaker fees make up the largest share, 84% of the total. Carl Zeiss Meditec, Inc. paid the most, $1,140.

Dmand AI lists 4 awards for Dr. Horowitz, most recently Super Doctors--Rising Stars in 2020. Dr. Horowitz serves on IRB4 Columbia University Institutional Review Board and Columbia University Medical Center Joint Radiation Safety Committee.

Dr. Horowitz graduated from The Johns Hopkins University School of Medicine in 2009. Dr. Horowitz is a member of AACR, ACR, ASTRO, ASCO and RSNA.

Dr. Horowitz is in network with 17 carriers, including Elevance, MVP Health Care and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.